GVS (GVS) Q1 2025 earnings summary

Executive summary

• Q1 2025 consolidated revenues rose 3.2% year-over-year to €107.2 million, driven by Healthcare & Life Sciences growth (+6.1%) and offsetting an 11% decline in Energy & Mobility.

• Adjusted EBITDA increased 6.1% to €25.8 million, with margin improving to 24.1% from 23.4% year-over-year.

• Adjusted net income (excluding FX) grew 21.6% to €12.0 million, with margin up to 11.2%.

• Leverage ratio post-acquisition at 2.5x, reflecting the Haemonetics Whole Blood acquisition.

• Acquisition of Haemonetics' whole blood assets completed in January 2025, strengthening the Transfusion Medicine segment.

Financial highlights

• Revenue grew 3.2% year-over-year to €107.2 million; underlying growth was 2.3% after FX adjustment.

• Adjusted EBITDA margin improved to 24.1%, up 70 bps year-over-year.

• Adjusted EBIT rose 9.3% to €18.8 million, with a 17.5% margin.

• Net financial debt increased to €275.6 million, mainly due to the Haemonetics acquisition.

• Cash and cash equivalents at period end were €56.1 million, down from €103.0 million at year-end.

Outlook and guidance

• FY 2025 guidance confirmed: mid- to high single-digit revenue growth, adjusted EBITDA margin up 150–250 bps, and leverage ratio below 2x by year-end.

• April and May sales are tracking in line with guidance, with acceleration expected in Q2 as exceptional Q1 events are recovered.

• New US tariffs expected to have limited impact (approx. 50 bps on adjusted EBITDA margin), mitigated by local production and USMCA compliance.